Hodgkin's lymphoma
Methodology & AI Transparency ⓘ
Hodgkin's lymphoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code C81.90 in Cancer & Oncology, Hodgkin's lymphoma requires immunohistochemistry [Hodgkin's lymphoma C81.90] so specialists can calibrate treatment intensity against Pathology / Molecular in Hodgkin's lymphoma (C81.90: Genomic Staging) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Hodgkin's lymphoma uses ICD-10 C81.90 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Clinicians assessing Hodgkin's lymphoma focus on microenvironment inflammation [Hodgkin's lymphoma C81.90] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Hodgkin's lymphoma: maintaining Pathology / Molecular in Hodgkin's lymphoma (C81.90: Genomic Staging) within Guideline-concordant surveillance (C81.90).
Ask our AI Specialists anything about Hodgkin's lymphoma
What Is Hodgkin's lymphoma?
Cataloged under federal diagnostic code C81.90 in Cancer & Oncology, Hodgkin's lymphoma requires immunohistochemistry [Hodgkin's lymphoma C81.90] so specialists can calibrate treatment intensity against Pathology / Molecular in Hodgkin's lymphoma (C81.90: Genomic Staging) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Hodgkin's lymphoma (C81.90) features microenvironment inflammation [Hodgkin's lymphoma C81.90]. therapeutic stabilization in cancer & oncology is verified against Complete Blood Count in Hodgkin's lymphoma (C81.90: (ANC, Hemoglobin, Platelets)).
Common Symptoms & Clinical Signs
- • Presentation of Hodgkin's lymphoma (C81.90): unexplained bleeding, chronic in Hodgkin's lymphoma (C81.90: hoarseness/cough, or progressive)
- • Secondary Hodgkin's lymphoma clinical sign: abnormality detected early in Hodgkin's lymphoma (C81.90: on age-appropriate screening)
- • Symptom flares in Hodgkin's lymphoma correlating with Pathology / Molecular in Hodgkin's lymphoma (C81.90: Genomic Staging) deviation outside Guideline-concordant surveillance (C81.90)
- • Functional cancer & oncology impact requiring immunohistochemistry [Hodgkin's lymphoma C81.90] evaluation (C81.90)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hodgkin's lymphoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C81.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Hodgkin's lymphoma (C81.90: Genomic Staging) | Guideline-concordant surveillance (C81.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Hodgkin's lymphoma (C81.90: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C81.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Hodgkin's lymphoma (C81.90: Organ Function Panel) | Preserved renal/hepatic clearance (C81.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hodgkin's lymphoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Gallium Citrate Ga-67 Gallium Citrate Ga-67 Generic • RxCUI RXN-69945180-1786 | FDA Prescription Therapeutic Agent | 89% | $0.5500 | $ 30.78 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hodgkin's lymphoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women: What a 1,116-Participant Study Found In postmenopausal women with ER+ breast cancer, adjuvant ibandronate 50 mg once daily does not improve DFS and should not be recommended as part of standard treatment regimens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2022-09-01 • Phase III Randomized Trial | N = 1,116 | 90/100 | PMID 35442755 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large B-cell lymph ClinicalTrials.gov Registry (NIH NLM) • 2013-03-04 • Completed Human Clinical Trial (NCT) | N = 23 | 89/100 | PMID NCT01030536 ↗ |
| Can This Approach Help? Inside the Latest Research on Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Improved long-term efficacy with R 2 versus R-placebo and manageable safety with R 2 were observed in patients with FL, including those 70 years and older. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-06-15 • Phase III Randomized Trial | N = 66 | 88/100 | PMID 41990300 ↗ |
| Managing Sarcomatoid kidney cell carcinoma: Can Add-on treatment Make a Real Difference? (What a 171-Person Study Found) Add-on treatment with sunitinib or sorafenib did not show an improvement in DFS or OS in patients with sRCC. BJU international • 2022-06-15 • Phase III Randomized Trial | N = 171 | 88/100 | PMID 34480522 ↗ |
| New Insights on High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung: What a 313-Participant Study Found Although 45-Gy twice-daily radiotherapy remains the standard of care, this study provides the most robust information available to help guide the choice of thoracic radiotherapy regimen for patients with limited-stage... Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2023-05-01 • Phase III Randomized Trial | N = 313 | 87/100 | PMID 36623230 ↗ |
Hodgkin's lymphoma Patient Community & “People Like Me” Threads
Filter Hodgkin's lymphoma community threads and patient logs by age, biological sex, dosage, and treatment duration.